BELGRADE, Maine, May 16, 2024
/PRNewswire/ -- Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical
device company (www.botimageai.com), introduced its Prostate Cancer
detection, diagnosis, and screening software to the Urologist
community at the recent AUA meeting in San Antonio, Texas and received rave reviews.
Urologists from around the world shared their comments that they
were all too often disappointed and distrusted the radiological
reports received from interpretation of prostate MRI as they
frequently missed cancers as well as created a large number of
false positives that the urologists then had to explain to their
clients, the patients.
Bot Image unveiled the fact that its
ProstatID™ software was also FDA-cleared for lesion
detection, segmentation AND classification. Dr. Randall Jones, CEO and founder of Bot Image
noted that "this level of performance is something quite unique in
this fast evolving industry. Other AI products provide some level
of physician aid to identifying suspect lesions, but ProstatID does
the heavy lifting of segmentation and classification by providing
physicians with a PI-RADS score as well as risk assessment score
for each lesion along a continuous scale from 1-99".
Every urologist that attended the Bot Image booth, was impressed
by the reported performance of the software (93.6% AUROC) but even
more expressive about the software's output reports that include
not only the colorized "heat map" indicating the location and
margins of the lesions on axial T2-weighted MRI images, but also
the unique indications in 3D views of the risk colored solid
lesions within translucent prostate organ. These views present
ideal targeting for Cognitive Fusion Guidance or can be utilized in
conjunction with FUSION guided treatment planning and
execution.
Dr. D. Russell Locke, a leading
urologist who uses ProstatID to review MRI scans on all of his
patients noted, after visiting all of the vendors at the AUA
meeting, that "ProstatID had the most significant impact on
Prostate cancer detection and treatment planning of any of the
products at this meeting". He went on to reiterate that "All
urologists should be using ProstatID".
info@botimageai.com
(402) 334-2525
Bot Image: See More, Treat Smarter
™
www.botimageai.com
Copyright Bot Image, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bot-image-inc-introduced-its-prostate-cancer-detection-diagnosis-and-screening-software-at-urologist-meeting-in-san-antonio-texas-302146778.html
SOURCE Bot Image Inc.